Funding To Fuel Growth in Sales and Marketing Expansion, International Markets and Innovation. The Stork® Products Are Available for Purchase Today In the United Kingdom and the United States.
(Pittsburgh, PA) December 19th, 2014 – Rinovum® Women’s Health, a privately held, U.S.-based women’s health company, announced today that it has secured $3 million in a series C financing from its existing investor base. The round was led by a private, Pennsylvania-based investment fund. Other participants included the Pittsburgh Life Sciences Greenhouse Accelerator Fund and BlueTree Allied Angels
Rinovum received FDA clearance for over-the-counter use of its product in July 2014 and, to date, has successfully launched in three markets: the United Kingdom, Canada and the United States.
The Stork products (The Stork® and The Stork® OTC) give couples a way to use cervical cap insemination — an established conception technique — in the privacy of home. The Stork OTC incorporates familiar elements (condom-like sheath for collection and tampon-like delivery and removal of the cap), so it can be used at home, in private, before having to try costly, in-clinic treatments (or after having already tried them) – and without loss of intimacy. The Stork® products are available to purchase at select retailers and online.
“It has been an amazing year for Rinovum and The Stork. The Stork products are now available without a prescription at major retailers in three countries. We serve a growing population seeking medically proven help on their path to conception, and we offer a solution that can be performed in the privacy of a couple’s home. Hearing feedback from customers who have become pregnant pushes us to continue the expansion worldwide, providing an easy and affordable solution for couples who are struggling to conceive” states […]